Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?

Canopy Growth reported fiscal Q1 2027 net revenue of $57.4 million, up 13% year over year, while its adjusted EBITDA loss narrowed 59% to $2.3 million and adjusted gross margin improved 600bps to 31%. The MTL Cannabis acquisition is expected to support a positive adjusted EBITDA result in fiscal 2027 through growth, vertical integration and roughly $7.2 million in annual cost savings. However, free-cash-flow outflow worsened to $18.5 million from $8.3 million, leaving sustained cash generation as the key remaining risk despite $241.4 million of cash and debt maturities extended to January 2031.

Analysis

The investable inflection is not adjusted EBITDA itself but whether the acquired cultivation base converts growth into cash without rebuilding inventory or receivables. A 600bp gross-margin improvement is meaningful only if it persists after integration accounting and promotional mix normalize; otherwise, the market is likely to value CGC/WEED as another serial-restructuring story rather than a self-funding operator. The widened cash outflow implies that a near-term EBITDA milestone could still be accompanied by dilution risk, particularly if working capital fails to reverse over the next two reported quarters.

MTL increases vertical integration, which should improve flower availability and reduce third-party procurement exposure, but it also raises execution risk: Canopy now needs to demonstrate that internal supply earns better realized pricing than wholesale alternatives. If successful, the more relevant competitive pressure falls on Canadian producers reliant on external biomass or lower-margin value channels, including TLRY, OGI, CRON and SNDL. The 6-18 month upside case is international medical-market mix expansion, where higher-quality supply can support margins; the near-term market will instead focus on post-acquisition revenue retention, inventory turns and operating-cash-flow conversion.

Consensus may over-credit a small EBITDA crossover because the company has ample time before debt maturity, reducing urgency but not eliminating equity dilution risk. The stock can rerate sharply over 1-3 months if the next two quarters show positive EBITDA and materially lower cash use, but failure to convert profitability into operating cash flow would likely compress the multiple regardless of revenue growth. Falsify the constructive thesis if gross margin retreats below 30%, MTL synergies are delayed beyond fiscal year-end, or cumulative free-cash outflow remains elevated through the second half of fiscal 2027.

Key Decisions for Investors

• Maintain CGC/WEED as a watchlist long rather than initiate on the EBITDA narrative alone; enter only after a second consecutive quarter of positive adjusted EBITDA and clear sequential improvement in operating cash flow. This targets a 1-3 month confirmation catalyst while avoiding a likely dilution-driven drawdown if cash conversion disappoints.
• For cannabis exposure, prefer a conditional pair trade long CGC/WEED versus short TLRY after verified cash-flow improvement: Canopy's integrated supply and synergy realization could support relative margin expansion, while the pair limits broad regulatory and risk-on/risk-off beta. Exit if CGC gross margin falls below 30% or the relative spread widens 15% against entry.
• Do not underwrite the stated annual cost savings until they appear in cash operating expenses and inventory turns; set an earnings alert for integration charges, receivables growth and inventory buildup. A sustained working-capital release is the necessary signal to upgrade from tactical trade to 6-18 month structural long.
• Avoid long-dated CGC calls until cash-flow confirmation because implied upside is vulnerable to financing headlines; if a position is required before results, size equity exposure small and define risk at the next earnings report rather than averaging down on an adjusted-EBITDA beat.